Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.

Rahman M, Baimbridge C, Davis BR, Barzilay JI, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C; ALLHAT Collaborative Research Group.

Clin Nephrol. 2013 Oct;80(4):235-48. doi: 10.5414/CN107922.

PMID:
23816477
[PubMed - indexed for MEDLINE]
2.

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C; ALLHAT Collaborative Research Group.

Am J Kidney Dis. 2008 Sep;52(3):412-24. doi: 10.1053/j.ajkd.2008.05.027. Epub 2008 Aug 3.

PMID:
18676075
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.

PMID:
12479764
[PubMed - indexed for MEDLINE]
4.

Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).

Margolis KL, Dunn K, Simpson LM, Ford CE, Williamson JD, Gordon DJ, Einhorn PT, Probstfield JL; ALLHAT Collaborative Research Group.

Am Heart J. 2009 Dec;158(6):948-55. doi: 10.1016/j.ahj.2009.10.001.

PMID:
19958861
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54. doi: 10.1111/jch.12139. Epub 2013 Jun 10.

PMID:
23889716
[PubMed - indexed for MEDLINE]
6.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.

PMID:
19216014
[PubMed - indexed for MEDLINE]
7.

[Clinical study of the month. The ALLHAT-LLT trial].

Kulbertus H, Scheen AJ.

Rev Med Liege. 2003 Jan;58(1):53-8. French.

PMID:
12647600
[PubMed - indexed for MEDLINE]
8.

Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT Jr, Barzilay JI, Brown CD, Colon PJ Sr, Fine LJ, Grimm RH Jr, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R; ALLHAT Collaborative Research Group.

Clin J Am Soc Nephrol. 2012 Jun;7(6):989-1002. doi: 10.2215/CJN.07800811. Epub 2012 Apr 5.

PMID:
22490878
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E.

Circulation. 2002 Mar 26;105(12):1424-8.

PMID:
11914249
[PubMed - indexed for MEDLINE]
Free Article
10.

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease).

Lancet. 2002 Apr 20;359(9315):1379-87. Erratum in: Lancet 2002 Nov 2;360(9343):1430.

PMID:
11978335
[PubMed - indexed for MEDLINE]
11.

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group.

J Am Coll Cardiol. 2009 Nov 24;54(22):2023-31. doi: 10.1016/j.jacc.2009.08.020.

PMID:
19926008
[PubMed - indexed for MEDLINE]
Free Article
12.

ALLHAT-LLT: questions, questions, and more questions (and some answers).

Skerrett PJ, Pasternak RC.

Curr Atheroscler Rep. 2004 Sep;6(5):375-80. Review.

PMID:
15296704
[PubMed - indexed for MEDLINE]
13.

Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.

Ford I, Bezlyak V, Stott DJ, Sattar N, Packard CJ, Perry I, Buckley BM, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J.

PLoS Med. 2009 Jan 20;6(1):e16. doi: 10.1371/journal.pmed.1000016.

PMID:
19166266
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.

PMID:
11889008
[PubMed - indexed for MEDLINE]
Free Article
15.

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.

Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators.

Am Heart J. 2003 Apr;145(4):643-51.

PMID:
12679760
[PubMed - indexed for MEDLINE]
16.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

PMID:
17408535
[PubMed - indexed for MEDLINE]
Free Article
17.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
[PubMed - indexed for MEDLINE]
18.

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A.

Ann Intern Med. 2001 May 15;134(10):931-40.

PMID:
11352694
[PubMed - indexed for MEDLINE]
19.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk